Long Shortz with Orthocell: 81% success rate validates Remplir as US rollout accelerates

Tylah Tully chats with Orthocell (ASX:OCC) CEO and managing director Paul Anderson after a new real-world study demonstrated a 81.1% treatment success rate for the company’s nerve repair device, Remplir.

Anderson explains why this real-world validation is so significant for surgeons, giving them greater confidence in achieving consistent and predictable outcomes for patients.

Orthocell’s U.S. rollout is progressing at pace, the company has already built a strong foundation with experienced staff, 15 distribution partners, and over 100 sales representatives.

But the company is eyeing global expansion beyond the U.S., highlighting opportunities in the EU, UK, and Brazil – all major markets for nerve repair.

Watch the video for more.

This video was developed in collaboration with Orthocell, a Stockhead client at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.